NCT02057718View on ClinicalTrials.gov

Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 1, 2014

Primary Completion Date

May 8, 2020

Study Completion Date

May 8, 2020

Conditions
Progressive Familial Intrahepatic Cholestasis (PFIC)
Interventions
DRUG

LUM001 (Maralixibat)

LUM001 also known as Maralixibat (MRX) oral dose up to twice a day (BID).

Trial Locations (10)

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19104

The Children's Hospital of Philadelphia, Philadelphia

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

69677

Hopital Femme Mere Enfant De Lyon, Bron

80045

Children's Hospital Colorado, Aurora

90027

Children's Hospital Los Angeles, Los Angeles

04-730

The Children's Memorial Health Institute, Warsaw

B4 6NH

Birmingham Children's Hospital, Birmingham

LS1 3EX

Leeds Teaching Hospital NHS Trust, Leeds

SE5 9RS

Kings College Hospital, London

Sponsors
All Listed Sponsors
lead

Mirum Pharmaceuticals, Inc.

INDUSTRY